Angiogenesis related Compound Library 
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, uncontrolled angiogenesis underlies many deadly and debilitating conditions, including cancer, skin diseases, immune disorders, diabetic ulcers, cardiovascular disease, stroke, critical limb ischemia, and many others. Therefore, angiogenesis has become an attractive target for combating diseases characterized by either poor vascularization or abnormal vasculature. For example, angiogenesis plays a critical role in the growth of cancer. Tumors induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g. VEGF) and proteins which induce capillary growth into the tumor, providing it with oxygen and nutrients. Angiogenesis is also required for the spread of a tumor, or metastasis. Therefore, angiogenesis inhibitors can be used to treat cancer. In addition, proangiogenic therapies are being explored as options to treat ischemic cardiovascular diseases by formation of "natural bypasses"—that is, collateral vessels.
The AnyMol's Angiogenesis related Compound Library, a unique collection of angiogenesis related compounds, can be used for research in angiogenesis and related drug discovery.
- All products & services are for research use only. Not for human or veterinary or therapeutic use.
- Pack Size
- 1 mg
- 10 μL x 10 mM (in DMSO)
- 30 μL x 10 mM (in DMSO)
- 50 μL x 10 mM (in DMSO)
- 100 μL x 10 mM (in DMSO)
Technical Information
Library Compound Information
Excel 
SDF - Packaging And Storage:
- Powder or pre-dissolved DMSO solutions in 96/384 well plate with optional 2D barcode
- Shipped with blue ice
- This compound library is provided at a concentration of 10 mM in DMSO. A small number of compounds may be provided in different solvents or concentrations due to solubility or stability requirements. Please refer to the specific product information for details.
- Product Description:
- A unique collection of 2300 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS);
- Targets include angiogenesis signaling, and related targets such as S1P, VEGFR, PDGF, etc.;
- Includes approved drugs targeting angiogenesis, such as Sunitinib Malate, Lenalidomide, sorafenib, Erlotinib; drugs in clinical development with the most potential targeting angiogenesis, such as Vatalanib, Orantinib, 2-Methoxyestradiol (Panzem), Celecoxib;
- Detailed compound information with structure, target, activity, IC50 value, and biological activity description;
- Structurally diverse, medicinally active, and cell permeable;
- NMR and HPLC validated to ensure high purity and quality;
